Beike Biotechnology
Stem cell therapy for spinal cord injury in China typically ranges from $18,000 to $35,000. Total costs depend on the cell type, the number of injections, and the length of rehabilitation. In the United States, patients usually pay around $32,500 for similar treatments. China provides a significant alternative, with average savings of approximately 45%. Standard packages often include medical evaluations, cell administration, and local transportation.
Bookimed Expert Insight: China is a global leader in cell processing standards. Beike Biotechnology operates over 20 laboratories following Good Manufacturing Practice (GMP) standards. They were the first to receive CNAS (China National Accreditation Service) accreditation for adult stem cells. Choosing clinics with ISO 9001 certification ensures high quality management. This infrastructure supports high success rates, including 95% quality-of-life improvements for similar neurological conditions.
| China | Turkey | Austria | |
| Stem cell therapy for spinal cord injury | ≈ $18,000 | from $10,300 | ≈ $9,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem cell therapy for spinal cord injury upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem cell therapy for spinal cord injury and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem cell therapy for spinal cord injury journey.
Dr. Sean Hu is a leader in biotechnology and stem cell therapy. He earned a PhD in biochemistry and molecular biology from the University of Gothenburg and Chalmers University of Technology in Sweden. He is the founder, chairman, and CEO of Shenzhen Beike Biotechnology Co., Ltd. He also serves as director of the Shenzhen Beike Cell Engineering Institute.
He was among the first experts recognized by China’s Thousand Talents Program. At Beike, he leads the development and commercialization of adult stem cell therapies. His work focuses on conditions of the brain and spinal cord, and on neurodegenerative and autoimmune disorders. His goal is to make high-quality care more accessible.